RT Journal Article SR Electronic T1 Methylene Blue in Place of Acridine Orange as a Photosensitizer in Photodynamic Therapy of Osteosarcoma JF In Vivo JO In Vivo FD International Institute of Anticancer Research SP 297 OP 303 VO 22 IS 3 A1 TAKAO MATSUBARA A1 KATSUYUKI KUSUZAKI A1 AKIHIKO MATSUMINE A1 HARUHIKO SATONAKA A1 KEN SHINTANI A1 TOMOKI NAKAMURA A1 ATSUMASA UCHIDA YR 2008 UL http://iv.iiarjournals.org/content/22/3/297.abstract AB We recently established a unique therapeutic modality for musculoskeletal sarcomas, combining acridine orange (AO) with photodynamic surgery (PDS), photodynamic therapy (PDT) and radiodynamic therapy (RDT); excellent results were obtained in the inhibition of local tumor recurrence after intralesional excision. However, AO is not yet approved for clinical use and intravenous injection. Therefore, methylene blue (MB), which has a very similar chemical structure to AO and is already in clinical use for other diseases, was investigated. In vitro studies using mouse osteosarcoma (LM8) cells revealed that MB-PDT had a strong cytocidal effect and that MB was not radiosensitive, showing no effect in RDT. In vivo studies showed that MB did not specifically accumulate in mouse osteosarcoma tissue and that it did not inhibit tumor growth. MB is not a better photosensitizer than AO in PDS, PDT and RDT for osteosarcoma.